薬物動態学研究室
薬物動態学研究室HOME > 山崎浩史教授の研究業績リスト

山崎浩史教授の研究業績リスト


ISI Indexed Name: ★YAMAZAKI H = "Highly cited researcher"


ISI Rating: Highly Cited
ISI Assigned Category: Pharmacology

原著 Original Papers　(過去３年分抜粋　last 3 years) A total of 237 papers

Last updated on 03/09/2012


  1. Nakada, T., Kiyotani, K., Iwano, S., Iwano, S., Uno, T., Yokohira, M., Yamakawa, K., Fujieda, M., Saito, T., Yamazaki, H., Imaida, K., and Kamataki, T. Lung tumorigenesis promoted by anti-apoptotic effects of cotinine, a nicotine metabolite through activation of PI3K/Akt pathway. J. Toxicol. Sci., in press.

  2. Tabuchi, N., Hattori, M., Shimizu, M., Koide, M., and Yamazaki, H. Evaluation of cytotoxic potential of cored soft contact lenses with adsorbed active ingredients from over-the-counter eye drops. J. Toxicol. Sci., in press.

  3. Yamazaki, H., Suemizu, H., Shimizu, M., Igaya, S., Shibata, N., Nakamura, N., Chowdhury, G., and Guengerich, F.P. In vivo formation of dihydroxylated and glutathione conjugate metabolites derived from thalidomide and 5-hydroxythalidomide in humanized TK-NOG mice. Chem Res Toxicol, 25, 274-276, 2012.[PubMed]

  4. Ise, R., Nakanishi, Y., Kohara, S., Yamashita, H., Yoshikawa, T., Iwasaki, K., Nagata, R., ., Fukuzaki, K., Utoh, M., Nakamura, C., Yamazaki, H., and Uno, Y. Expression profile of hepatic genes in cynomolgus macaques bred in Cambodia, China, and Indonesia: implications for cytochrome P450 genes. Drug Metab.Pharmacokinet,. in press[PubMed]

  5. Uehara, S., Murayama, N., Yamazaki, H., and Uno, Y. CYP2C76 non-synonymous variants in cynomolgus and rhesus macaques. Drug Metab.Pharmacokinet., in press. [PubMed]

  6. Kuribayashi, S., Uno, Y., Naito, S., and Yamazaki, H. Different metabolites of human hepatotoxic pyrazolopyrimidine derivative 5-n-butyl-pyrazolo[1,5-a]pyrimidine produced by human, rat, and monkey cytochrome P450 1A2 and liver microsomes. Basic Clin.Pharmacol.Toxicol., in press.[PubMed]

  7. Shimizu, M., Kiyotani, K., Kunitoh, H., Kamataki, T., and Yamazaki, H. Different effects of TERT, TP63, and CYP2A6 polymorphism on individual risk of tobacco-related lung cancer in male Japanese smokers. J.Cancer Ther., 2, 690-696, 2011.{Open access]

  8. Aoyama, T., Hirata, K., Hirata, R., Yamazaki, H., Yamamoto, Y., Hayashi, H., and Matsumoto, Y. Population pharmacokinetics of fluconazole after administration of fosfluconazole and fluconazole in critically ill patients. J. Clin. Pharm.Ther., in press [PubMed]

  9. Uehara, S., Murayama, N., Nakanishi, Y., Zeldin, D. C., Yamazaki, H., and Uno, Y. Immunochemical detection of cytochrome P450 enzymes in liver microsomes of 27 cynomolgus monkeys. J.Pharmacol.Exp.Ther., 339, 654-661, 2011. [PubMed]

  10. Uno, Y., Uehara, S., and Yamazaki, H. Discovery of genetic variants in CYP1D1: implication for functional integrity of CYP1D1 in cynomolgus macaques and rhesus macaques. Drug Metab.Pharmacokinet, 26, 627-631, 2011.[PubMed]

  11. Ise, R., Kondo, S., Kato, H., Imai, N., Akiyama, H., Iwasaki, K., Yamazaki, H., and Uno, Y. Expression of cytochromes P450 in fetal, infant, and juvenile liver of cynomolgus macaques. Drug Metab.Pharmacokinet, 26, 621-626, 2011. [PubMed]

  12. Shimada, T., Murayama, N., Tanaka, K., Takenaka, S., Guengerich, F. P., Yamazaki, H., and Komori, M. Spectral modification and catalytic inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2A6 and 2A13 by four chemopreventive organoselenium compounds. Chem. Res. Toxicol., 24, 1327-1337, 2011[PubMed]

  13. Kansaku, F, Kumai, T., Sasaki, K., Yukozuka, M., Shimizu, M., Tateda, T., Murayama, N., Kobayashi, S., and Yamazaki, H. Individual differences in pharmacokinetics and pharmacodynamics of anesthetic agent propofol with regard to CYP2B6 and UGT1A9 genotype and patient Age. Drug Metab.Pharmacokinet., 26, 532-537, 2011.[PubMed]

  14. Butturini,E., Cavalieri,E., Carcereri de,P.A., Darra,E., Rigo,A., Shoji,K., Murayama,N., Yamazaki,H., Watanabe,Y., Suzuki,H., and Mariotto,S. Two naturally occurring terpenes, dehydrocostuslactone and costunolide, decrease intracellular GSH content and inhibit STAT3 activation. PLoS One, 6, e20174, 2011[PubMed]

  15. Shibahara, N., Masunaga, Y., Iwano, S., Yamazaki, H., Kiyotani, K., and Kamataki, T. Human cytochrome P450 1A1 is a novel target gene of liver X receptor alpha;. Drug Metab.Pharmacokinet., 6, 451-457, 2011.[PubMed]

  16. Uno, Y. Matsuno, K, Murayama, N. Nakamura, C., and Yamazaki, H. Metabolism of P450 probe substrates by cynomolgus monkey CYP2C76. Basic Clin.Pharmacol.Toxicol.,109, 315-318, 2011.[PubMed]

  17. Niwa, T., Murayama, N., Umeyama, H., Shimizu, M., and Yamazaki, H. Human liver enzymes responsible for metabolic elimination of tyramine, a vasopressor agent from daily food. Drug Metab.Lett.,5, 216-219, 2011[PubMed]

  18. Uno, Y., Matsushita, A, and Yamazaki, H. CYP1B1 is polymorphic in cynomolgus and rhesus macaques. J.Ved.Med.Sci., 73, 1129-1231, 2011.[PubMed]

  19. Ueng, Y.-F., Chen, C.-C., Chung, Y.-T, Liu, T.-Y., Chang, Y.-P., Lo, W.-S., Murayama, N., Yamazaki, H., Soucek, P., Chau, G.-Y., Chi, C.-W., and Chen, R.-M. Li D. T. Mechanism-based inhibition of cytochrome P450 (CYP) 2A6 by chalepensin in recombinant systems, in human liver microsomes and mice in vivo. Brit..J. Pharmacol., 163, 1250-1262, 2011.[PubMed]

  20. Azuma, K., Lezhava, A., Shimizu, M., Kimura, Y., Ishizu, Y., Ishikawa, T., Kamataki,T. Hayashizaki,　Y. and Yamazaki，H.. Direct genotyping of cytochrome P450 2A6 whole gene deletion from human blood samples by the SmartAmp method. Clin.Chim.Acta, 412, 1249-1251, 2011.[PubMed]

  21. Emoto, C., Iwasaki, K., Koizumi, R., Utoh, M., Murayama, N., Uno Y., and Yamazaki, H. Species difference between cynomolgus monkeys and humans on cytochromes P450 2D and 3A-dependent drug oxidation activities in liver microsomes. J.Health Sci., 57, 164-170, 2011.[PDF]

  22. Sugiyama, M., Fujita, K., Murayama, N., Akiyama, Y., Yamazaki, H., and Sasaki, Y.. Sorafenib and sunitinib, two anti-cancer drugs, inhibit CYP3A4- and activate CYP3A5-mediated midazolam 1' hydroxylation. Drug Metab.Dispos.,39, 757-762, 2011.[PubMed]

  23. Uno, Y., Uehara, S. Kohara, S., Iwasaki, K., Nagata, R., Fukuzaki, K., Utoh, M., Murayama, N., and Yamazaki, H. Newly identified CYP2C93 is a functional enzyme in rhesus monkey, but not in cynomolgus monkey. PLoS ONE, 6, e16923, 2011.[PloS One]

  24. Yamazaki, H., Suemizu, H., Igaya, S., Shimizu, M., Shibata, N., Nakamura, M., Chowdhury, G. and Guengerich, F. P. In vivo formation of a glutathione conjugate derived from thalidomide in humanized uPA-NOG mice. Chem.Res.Toxicol., 24, 287–289, 2011[PubMed]

  25. Shimizu, M., Denton, T., Kozono, M., Cashman, J. R., Leeder, J. S., and Yamazaki, H. Developmental variations in metabolic capacity of flavin-containing monooxygenase 3 in childhood. Bri. J. Clin. Pharmacol. 71, 585–591, 2011[PubMed]

  26. Ise, R., Uehara, S., Akiyama, H., Kondo, S., Iwasaki, K., Nagata, R., Nobumasa, H., Yamazaki, H. and Uno, Y. A newly developed DNA microarray is useful to assess induction of cytochromes P450 in cynomolgus monkey. Drug Metab. Pharmacokinet.,26, 228-235, 2011.[PubMed]

  27. Akiyoshi, T. Saito, T., Murase, S., Miyazaki, M. Murayama, N. Yamazaki, H., Guengerich, F.P., Nakamura, K., Yamamoto, K., and Ohtani, H. Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants. Drug Metab.Dispos. 39, 724–728, 2011[PubMed]

  28. Uno Y, Uehara, S., Murayama, N. and Yamazaki,H. CYP2G2, pseudogenized in human, is expressed in nasal mucosa of cynomolgus monkey and encodes a functional drug-metabolizing enzyme. Drug Metab.Dispos., 39, 717–723, 2011[PubMed]

  29. Uno, Y., Matsuno, K., Nakamura, C., Utoh, M., and Yamazaki, H.. Cynomolgus macaque CYP4 isoforms are functional, metabolizing arachidonic acid. J.Ved.Med.Sci.,73, 487-490, 2011.[PubMed]

  30. Nakamura, K., Mizutani, R., Sanbe, A.,Enosawa, S., Kasahara, M., Nakagawa, A., Ejiri, Y., Murayama, N., Miyamoto, Y., Torii, T., Kusakawa, S., Yamauchi, J., Fukuda, M., Yamazaki, H., and Tanoue. A., Evaluation of drug toxicity with hepatocytes cultured in a micro-space cell culture system . J.Biosci.Bioeng., 111, 78-84, 2011.[PubMed]

  31. Uno, Y., Uehara, S., Murayama, N. and Yamazaki, H.. CYP1D1, pseudogenized in human, is expressed and encodes a functional drug-metabolizing enzyme in cynomolgus monkey. Biochem.Pharmacol. 81，442-450, 2011.[PubMed]

  32. Shimada, T., Tanaka, K., Takenaka, T., Murayama, N., Martin, M. V., Foroozesh, M. K. Yamazaki,H., Guengerich, F. P, and Komori. M. Structure-function relationships of inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 flavonoid derivatives. Chem.Res.Toxicol. 23, 1921-1935, 2010.[PubMed]

  33. Yamazaki, H., Horiuchi, K., Takano, R., Nagano, T., Shimizu, M.. Kitajima, M., Murayama, N. and Shono, F. Human blood concentrations of cotinine, a biomonitoring marker for tobacco smoke, extrapolated from nicotine metabolism in rats and humans and physiologically based pharmacokinetic modeling. Int.J.Environ.Res.Public Health, 7, 3406-3421, 2010.[Open access]

  34. Nagano, T., Shimizu, M. Kiyotani, K., Kamataki, T., Takano, R., Murayama, N., Shono, F., and Yamazaki, H. . Biomonitoring of urinary cotinine concentrations associated with plasma levels of nicotine metabolites after daily cigarette smoking in a male Japanese population. Int.J.Environ. Res.Public Health, 7, 2953-2964, 2010.[Open access]

  35. Kiyotani, K., Shimizu, M., Kumai, T., Kamataki, T., Kobayashi, S., and Yamazaki, H. Limited effects of frequent CYP2D6*36-*10 tandem duplication allele on in vivo dextromethorphan metabolism in a Japanese population. Eur.J.Clin.Pharmacol., 66, 1065-1068, 2010,[PubMed]

  36. Yamazaki, H., Takano, R., Horiuchi, K., Shimizu, M., Murayama, N., Kitajima, M., and Shono, F. Human blood concentrations of dichlorodiphenyltrichloroethane (DDT) extrapolated from metabolism in rats and humans and physiologically based pharmacokinetic modeling. J.Health Sci. 56, 566-575, 2010.[PDF]

  37. Ohtsuka, T.,Yoshikawa, T., Kozakai, K., Tsuneto, Y., Uno, Y., Utoh, M., Yamazaki, H. and Kume, T.. Alprazolam as an in vivo probe for studying induction of CYP3A in cynomolgus monkeys. Drug Metab.Dispos. 38, 1806-1813, 2010. [PubMed]

  38. Takano, R., Murayama,N., Horiuchi, K., Kitajima, M., Kumamoto, M., Shono, F., and Yamazaki. H. Blood concentrations of acrylonitrile in humans after oral administration extrapolated from in vivo rat pharmacokinetics, in vitro human metabolism, and physiologically based pharmacokinetic modeling. Regul.Toxicol Pharmacol., 58, 252-258, 2010.[PubMed]

  39. Uehara, S., Murayama, N., Yamazaki, H. and Uno,Y.. A novel CYP2A26 identified in cynomolgus monkey liver metabolizes coumarin. Xenobiotica, 40, 621-629, 2010..[PubMed]

  40. Uno, Y., Uehara, S., Kohara, S. Murayama, N. and Yamazaki, H. Cynomolgus monkey CYP2D44 newly identified in liver, metabolizes bufuralol and dextromethorphan Drug Metab.Dispos., 38, 1486-1492, 2010..[PubMed]

  41. Takano, R., Murayama, N., Horiuchi, K., Kitajima, M., Shono, F., and Yamazaki, H.. Blood concentrations of 1,4-dioxane in humans after oral administration extrapolated from in vivo rat pharmacokinetics, in vitro human metabolism, and physiologically based pharmacokinetic modeling. J.Health Sci., 56, 557-565, 2010. [PDF]

  42. Chowdhury, G. ., Murayama, N., Okada, Y., Uno, Y., Shimizu, M., Shibata, N., Guengerich, F. P., and Yamazaki, H. Human liver microsomal cytochrome P450 3A enzymes involved in thalidomide 5-hydroxylation and formation of a glutathione conjugate. Chem.Res.Toxicol.,23, 1018-1024, 2010[PubMed]

  43. Iwasaki, K., Murayama, N., Koizumi, R., Uno, Y., and Yamazaki, H. Comparison of cytochrome P450 3A enzymes in cynomolgus monkeys and humans. Drug Metab.Pharmacokinet., 25, 388-391, 2010.[PubMed]

  44. Yamazaki, H., Kuribayashi, S., Inoue, T., Tateno, C., Nishikura, Y., Oofusa, K., Harada, D., Naito, S., Horie, T., and Ohta, S. Approach for in vivo protein bindings of 5-n-butyl-pyrazolo[1,5-a]pyrimidine bioactivated in chimeric mice with humanized liver by two-dimensional electrophoresis with accelerator mass spectrometry. Chem Res Toxicol. 23, 152-158, 2010.[PubMed]

  45. Uno, Y., Matsushita, A., Osada, N., Uehara, S., Kohara, S., Nagata, R., Fukuzaki, K., Utoh, M., Murayama, N., and Yamazaki, H. Genetic variants of CYP3A4 and CYP3A5 in cynomolgus and rhesus macaques. Drug Metab.Dispos. 38, 209-214, 2010. [PubMed]

  46. Uno, Y., Matsuno, K., Nakamura, C., Utoh, M., and Yamazaki, H.. Identification and characterization of CYP2C18 in cynomolgus macaque (Macaca fascicularis). J. Vet. Med. Sci., 72, 225-228, 2010. [PubMed]

トリメチルアミン尿症関連の過去の論文
  1. Shimizu, M., Kozono, M., Murayama, N., and Yamazaki, H., Bonitos with low contents of malodorous trimethylamine as palliative cares for self-reported Japanese trimethylaminuria subjects. Drug Metab. Pharmacokinet,24,549-552,2009 [PubMed]
  2. Nagashima, S., Shimizu, M., Yano, H., Murayama, N., Kumai, T., Kobayashi, S., Guengerich, F.P., and Yamazaki, H. Inter-individual variation in flavin-containing monooxygenase 3 in livers from Japanese: correlation with hepatic transcription factors. Drug Metab.Pharmacokin., 24, 218-225, 2009.[PubMed]
  3. Shimizu, M., Murayama, N., Nagashima, S., Fujieda, M. and Yamazaki, H.. Complex mechanism underlying transcriptional control of the haplotyped flavin-containing monooxygenase 3 (FMO3) gene in Japanese: Different regulation between mutations in 5'-upstream distal region and common element in proximal region. Drug Metab.Pharmacokinet., 23: 54-58, 2008.[PubMed]
  4. Shimizu, M., Tomioka, S., Murayama, N. and Yamazaki, H. Missense and nonsense mutations of the flavin-containing monooxygenase 3 gene in a Japanese cohort. Drug Metab.Pharmacokinet., 22: 61-64, 2007.[PubMed]
  5. Yamazaki H, Fujita H, Gunji T, Zhang Z, Kamataki T, Cashman JR, and Shimizu, M. Stop codon mutations in the flavin-containing monooxygenase 3 (FMO3) gene responsible for trimethylaminuria in a Japanese population. Mol. Genet. Metab., 90: 58-63, 2007.[PubMed]
  6. Shimizu, M., Fujita, H., Aoyama, T., Yamazaki, H. Three novel single nucleotide polymorphisms (SNPs) of the FMO3 gene in a Japanese population. Drug Metab. Pharmacokinet., 21: 245-247, 2006[PubMed]
  7. Yamazaki, H., Fujieda,M., Cashman,J.R, and Kamataki,T. Mild trimethylaminuria observed in a Japanese cohort with liver damage. Am.J.Med., 118: 803-805, 2005.[PubMed]
  8. Yamazaki, H., Fujieda,M., Togashi,M., Saito,T., Preti,G., Cashman,J.R. and Kamataki,T. Effects of the dietary supplements, activated charcoal and copper chlorophyllin, on urinary excretion of trimethylamine in Japanese trimethylaminuria patients, Life Sci., 74: 2739-2747, 2004.[PubMed]
  9. Fujieda, M., Yamazaki, H., Togashi, M., Saito, T., and Kamataki, T. Two novel single nucleotide polymorphisms (SNPs) of the FMO3 gene in Japanese. Drug Metab.Pharmacokinet., 18: 333-335, 2003.[PubMed]

総説・著書 Reviews/Books　(過去３年分抜粋　last 3 years)

  1. Niwa, T. and Yamazaki, H. Comparison of cytochrome P450 2C subfamily members in terms of drug oxidation rates and substrate inhibition. Curr.Drug Metab., in press.
  2. Niwa, T., Murayama, N., and Yamazaki, H. Stereoselectivity of human cytochrome P450 in metabolic and inhibitory activities. Curr.Drug Metab., in press..[PubMed]
  3. Niwa, T., Murayama, N., and Yamazaki, H. Comparison of cytochrome P450 2D6 and variants in terms of drug oxidation rates and substrate inhibition. Curr.Drug Metab., 12, 412-435, 2011.[PubMed]
  4. Uno, Y., Iwasaki, K., Yamazaki,H. and Nelson, D.R. Macaque cytochromes P450: nomenclature, transcript, gene, genomic structure, and function. Drug Metab. Rev; 43, :346-361, 2011[PubMed]
  5. Sugiyama, A., Nakamura, Y., Akie, Y., Saito, H., Izumi, Y., Yamazaki, H., Kaneko, N., and Itoh, K. Microminipig, a non-rodent experimental animal optimized for life science research: In vivo proarrhythmia models of drug-induced long QT syndrome: development of chronic atrioventricular block model of Microminipig. J.Pharmacol.Sci.,115, 122-126, 2011.[PubMed]
  6. Emoto, C., Iwasaki, K., Murayama, and Yamazaki, H. Drug metabolism and toxicity in chimeric mice with humanized liver, J. Health, Sci., 57, 22-27, 2011.[PDF]
  7. 岩﨑一秀、山崎浩史、薬物動態が原因で開発あるいは販売が中止となった事例の分析とそこから学ぶこと、Pharm Stage 10, 6-8, 2011
  8. Emoto, C., Murayama, N., Rostami-Hodjegan, A., and Yamazaki, H.. Methodologies for investigating drug metabolism at the early drug discovery stage: Prediction of hepatic drug clearance and P450 contribution. Curr.Drug Metab., 11, 678-685, 2010.[PubMed]
  9. 山崎浩史、ヒト特異的代謝物とマイクロドージング、杉山雄一編　遺伝子医学MOOK別冊「創薬技術の革新：マイクロドーズからPET分子イメージングへの新展開」、2010, pp, 76-79.
  10. 鎌滝哲也、山崎浩史、薬物・外来異物に対する生体の代謝機構，「分子予防環境医学改訂版」，本の泉社，分子予防環境医学研究会編，東京，pp.94-104, 2010.
  11. 山崎浩史、清水万紀子、特異な体臭と代謝物分析：トリメチルアミン尿症を例として、ぶんせき、430, 510-512, 2010
  12. Niwa, T. Murayama, N. and Yamazaki, H. Comparison of the contributions of cytochromes P450 3A4 and 3A5 in drug oxidation rates and substrate inhibition. J. Health. Sci., 56, 239-236, 2010.[PDF]
  13. Yamazaki, H., Nakamoto, M., Shimizu, M., Murayama, N., and Niwa, T. Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles. Br.J.Clin.Pharmacol. 69:593-597, 2010.[PubMed]
  14. 山崎浩史、患者さんのための薬物動態学、薬剤学 70, 188-192, 2010.

    編集教科書

    医療薬物代謝学
    薬物動態学
    このページの先頭へ